Windlas Biotech (NSE:WINDLAS) Accounts Payable: ₹2,385 Mil (As of Mar. 2026)


NSE:WINDLAS Windlas Biotech Ltd NSE:WINDLAS
92 GF Score
Price ₹829.95
GF Value ₹938.90
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Windlas Biotech Accounts Payable?

Windlas Biotech NSE:WINDLAS +0.49% 92 Accounts Payable is ₹2,385 Mil as of Mar. 2026. GuruFocus rates NSE:WINDLAS with a GF Score™ of 92/100 and a GF Value™ of ₹938.90 (Modestly Undervalued). The stock has 1 warning sign investors should review.

Windlas Biotech's Accounts Payable for the quarter that ended in Mar. 2026 was ₹2,385 Mil.

Windlas Biotech's quarterly Accounts Payable declined from Sep. 2025 (₹1,929 Mil) to Dec. 2025 (₹0 Mil) but then increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹2,385 Mil).

Windlas Biotech's annual Accounts Payable increased from Mar. 2024 (₹1,315 Mil) to Mar. 2025 (₹1,778 Mil) and increased from Mar. 2025 (₹1,778 Mil) to Mar. 2026 (₹2,385 Mil).

Windlas Biotech Accounts Payable Related Terms

Windlas Biotech Accounts Payable Historical Data

* Premium members only.

The historical data trend for Windlas Biotech's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Windlas Biotech Accounts Payable Chart

Windlas Biotech Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Accounts Payable
Get a 7-Day Free Trial 632.32 877.43 1,315.11 1,778.39 2,384.93

Windlas Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,778.39 0.00 1,929.36 0.00 2,384.93
NSE:WINDLAS
92GF Score
Windlas Biotech Ltd NSE:WINDLAS
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Windlas Biotech Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of ₹2,385 Mil mean?
Windlas Biotech (NSE:WINDLAS) has a Accounts Payable of ₹2,385 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Windlas Biotech and its competitors.
Is Windlas Biotech's Accounts Payable too high?
Windlas Biotech's current Accounts Payable is ₹2,385 Mil. Overall, Windlas Biotech has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Windlas Biotech's Accounts Payable compare to ZTS and UTHR?
Windlas Biotech's Accounts Payable of ₹2,385 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Drug Manufacturers company?
A good Accounts Payable depends on the Drug Manufacturers industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Windlas Biotech and its competitors. Windlas Biotech's current Accounts Payable is ₹2,385 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Windlas Biotech stock overvalued right now?
Based on GuruFocus' analysis, Windlas Biotech (NSE:WINDLAS) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹938.90, compared to a current price of ₹829.95 — trading 11.6% below its estimated fair value. The current Accounts Payable is ₹2,385 Mil. Windlas Biotech's overall GF Score™ is 92/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Windlas Biotech (NSE:WINDLAS), the current Accounts Payable is ₹2,385 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Windlas Biotech (NSE:WINDLAS) Overvalued in 2026?

Based on GuruFocus' analysis, Windlas Biotech stock appears to be undervalued. The current stock price of ₹829.95 is trading 11.6% below its estimated GF Value™ of ₹938.90. GuruFocus considers Windlas Biotech to be Modestly Undervalued.

Key valuation signals for NSE:WINDLAS:

  • Accounts Payable: ₹2,385 Mil
  • GF Value™: ₹938.90 vs. price of ₹829.95 (11.6% below fair value)
  • GF Score™: 92/100 with 1 warning sign

No single metric tells the full story. See the NSE:WINDLAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Windlas Biotech Business Description

Other Exchanges 543329:India
Address Golf Course Extension Road, 705-706, Vatika Professional Point, Sector-66, Gurgaon, HR, IND, 122 001
Windlas Biotech Ltd is a pharmaceutical formulation contract development and manufacturing organization. The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics.
92GF Score

Get the complete analysis for NSE:WINDLAS

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹829.95
Price
₹938.90
GF Value